SPC Financial Inc. increased its stake in Celgene Corporation (NASDAQ:CELG) by 4.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,135 shares of the biopharmaceutical company’s stock after buying an additional 310 shares during the period. SPC Financial Inc.’s holdings in Celgene Corporation were worth $927,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of CELG. BKD Wealth Advisors LLC raised its stake in Celgene Corporation by 3.6% in the first quarter. BKD Wealth Advisors LLC now owns 3,817 shares of the biopharmaceutical company’s stock worth $475,000 after buying an additional 133 shares during the last quarter. Atria Investments LLC raised its stake in Celgene Corporation by 29.4% in the first quarter. Atria Investments LLC now owns 19,336 shares of the biopharmaceutical company’s stock worth $2,406,000 after buying an additional 4,389 shares during the last quarter. Baldwin Brothers Inc. MA raised its stake in Celgene Corporation by 103.1% in the first quarter. Baldwin Brothers Inc. MA now owns 7,670 shares of the biopharmaceutical company’s stock worth $954,000 after buying an additional 3,894 shares during the last quarter. Tompkins Financial Corp raised its stake in Celgene Corporation by 5.1% in the first quarter. Tompkins Financial Corp now owns 18,052 shares of the biopharmaceutical company’s stock worth $1,807,000 after buying an additional 870 shares during the last quarter. Finally, Viking Fund Management LLC acquired a new stake in Celgene Corporation during the first quarter worth about $809,000. 79.43% of the stock is owned by institutional investors.

Celgene Corporation (CELG) traded up 0.78% on Tuesday, reaching $132.68. 1,068,553 shares of the company’s stock were exchanged. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market capitalization of $103.80 billion, a PE ratio of 41.09 and a beta of 1.89. The company has a 50 day moving average price of $133.39 and a 200-day moving average price of $125.39.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the prior year, the firm posted $1.44 EPS. The business’s revenue was up 18.7% compared to the same quarter last year. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/29/celgene-corporation-celg-stake-boosted-by-spc-financial-inc.html.

CELG has been the subject of a number of research reports. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 target price (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and upped their target price for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 6th. Finally, Cann reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $147.38.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 253,761 shares of company stock worth $33,792,445. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.